Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press Releases

All Releases
View Summary FDA Advisory Committee Votes that Qapzola™ (apaziquone) Has Not Shown Substantial Evidence of a Treatment Effect Over Placebo
Sep 14, 2016
PDF 13.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Second Quarter 2016 Financial Results and Pipeline Update
Aug 9, 2016
PDF 42.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Second Quarter 2016 Financial Results Teleconference and Webcast
Aug 2, 2016
PDF 14.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation
Jul 13, 2016
PDF 13.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Cantor Fitzgerald's 2nd Annual Healthcare Conference on July 13th
Jul 6, 2016
PDF 13.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2016 Healthcare Conference on June 8th
Jun 1, 2016
PDF 13.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights an Oral Presentation on Apaziquone at the 2016 Annual Meeting of the American Urological Association Education and Research Inc. (AUA) in San Diego, California, May 6-10, 2016
May 6, 2016
PDF 15.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports First Quarter 2016 Financial Results and Pipeline Update
May 5, 2016
PDF 37.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016 Healthcare Conference on May 10th
May 3, 2016
PDF 13.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast
Apr 28, 2016
PDF 14.5 KB Add to Briefcase
View Summary FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma
Apr 20, 2016
PDF 73.2 KB Add to Briefcase
View Summary FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection
Mar 15, 2016
PDF 74.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update
Mar 9, 2016
PDF 45.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
Mar 7, 2016
PDF 16.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast
Mar 2, 2016
PDF 14.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at 2016 RBC Capital Markets' Global Healthcare Conference on February 24
Feb 22, 2016
PDF 13.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation)
Feb 19, 2016
PDF 12.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Begins Enrolling Patients in Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Jan 29, 2016
PDF 20.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Signs a Strategic Partnership With Servier Canada
Jan 11, 2016
PDF 17.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Registrational Trial of SPI-2012, a Novel, Long Acting G-CSF in Patients with Breast Cancer
Dec 16, 2015
PDF 18.9 KB Add to Briefcase
Showing 1-20 of 685 Page: 1 2 3 4 5 ... 35  Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
4.72
Change:
- 0.09
Day High:
4.89
Day Low:
4.67
Volume:
676,146
4:00 PM ET on Sep 23, 2016
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR